CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-Country, Multi-Centre Phase IV Study
Phase of Trial: Phase IV
Latest Information Update: 13 Oct 2012
At a glance
- Drugs Quetiapine (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms CARE-II
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 30 Oct 2008 Planned number of patients was 200, the actual number enrolled was 7, according to ClinicalTrials.gov record.
- 30 Oct 2008 Status changed from not yet recruiting to discontinued according to ClinicalTrials.gov record.